On July 25th, European regulators said no to Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. The European Medicines Agency (Europe’s version…
At the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, scientists and drug development companies gathered to report on recent successes…
For years, a commonly prescribed treatment for managing the symptoms of Alzheimer’s disease has been a type of drug called a cholinesterase inhibitor (ChEI)….
Parasites take an enormous toll on human and veterinary health. But researchers may have found a way for patients with brain disorders and a…
The new monoclonal anti-amyloid Alzheimer’s drugs are a constant source of controversy among doctors, insurers, and regulators worldwide. One of this buzzy new drug class,…
Athira Pharma’s experimental Alzheimer’s drug fosgonimeton hit a speedbump on its way toward FDA approval: The treatment failed to show a clinical benefit in…
In February, Biogen announced it was pulling Aduhelm off the market. The company will continue supplying the drug until November but stopped providing it…
Members of the Being Patient community are increasingly curious to learn their genetic status as it relates to Alzheimer’s risk. A story I was…
During the Alzheimer’s Association International Conference in Philadelphia last week, researchers and drug companies presented data on a range of different Alzheimer’s drugs. Amidst…
On July 25th, European regulators said no to Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. The European Medicines Agency (Europe’s version…
Cassava Sciences’ experimental Alzheimer’s drug simufilam is currently in clinical trials. Meanwhile, the company is experiencing a major shake-up. Its CEO and lead neuroscientist…
A new drug for Alzheimer’s was just this month approved by the FDA for use in the United States, in people in the earliest…
There are more than 500 active clinical trials for Alzheimer’s and other dementias in the U.S. They are designed to test different interventions, such…
UPDATED JULY 3: The Food and Drug Administration has approved Kisunla (generic name donanemab), a new Alzheimer’s drug developed by Eli Lilly. The published data…
A new anti-amyloid drug for Alzheimer’s disease might receive FDA approval as soon as this month. Although anti-amyloid drugs have shown us that clear…